Tumor-Infiltrating Lymphocyte Therapy Market

Author : John snow | Published On : 07 Apr 2026

Over the past decade, cell-based immunotherapy has emerged as one of the most promising approaches in oncology, particularly for the treatment of solid tumors. Among these innovations, tumor-infiltrating lymphocyte (TIL) therapy has gained considerable traction due to its personalized mechanism and ability to harness the patient’s own immune system. Companies such as Iovance Biotherapeutics, Obsidian Therapeutics, Biosyngen, and KSQ Therapeutics are actively advancing TIL-based treatments, contributing to the rapid evolution and expansion of the global TIL therapies market.

DelveInsight’s report on Tumor-Infiltrating Lymphocyte Therapies provides a comprehensive evaluation of market size, target patient population, competitive dynamics, and long-term forecasts. The analysis offers detailed insights into current treatment paradigms and the addressable patient base across major oncology indications, including melanoma, cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, head and neck squamous cell carcinoma (HNSCC), colorectal cancer, and other solid tumors. These indications have been selected based on both approved therapies and active pipeline development, ensuring a realistic representation of future market opportunities. Additionally, the report explores emerging TIL therapies, individual therapy market shares, and projected growth trends across the seven major markets (7MM) from 2020 through 2034.

According to DelveInsight’s findings, the TIL therapies market across the 7MM is expected to witness substantial expansion by 2034, driven by increasing clinical adoption and a growing eligible patient pool. The report quantifies patient populations across multiple tumor types, highlighting significant unmet needs in advanced cancers where existing immunotherapies often fall short. Companies like Obsidian Therapeutics, Biosyngen, and KSQ Therapeutics are progressing innovative candidates such as OBX-115, BST02, KSQ-001 EX, and KSQ-004 EX, all of which have the potential to enter the commercial landscape in the coming years.

Recent developments underscore the accelerating momentum in this field. In June 2025, Iovance Biotherapeutics published final data from the Phase II C-144-01 trial of AMTAGVI in the Journal of Clinical Oncology, along with five-year follow-up results presented at the 2025 ASCO Annual Meeting. These data reinforced the durability of response in patients with advanced melanoma. Around the same time, Obsidian Therapeutics shared early Phase I safety and efficacy results from its Agni-01 multicenter study evaluating OBX-115, presented at the 2025 ASCO Annual Meeting. In April 2025, KSQ Therapeutics announced the dosing of the first patient in its Phase I/II trial of KSQ-004EX, a CRISPR-engineered TIL therapy designed to enhance persistence and tumor-killing capability by knocking out SOCS1 and Regnase-1 genes. This gene-editing approach represents a significant step forward in improving the functional performance of TIL therapies.

Discover which indication is expected to grab the major tumor-infiltrating lymphocyte therapies market share @ Tumor-Infiltrating Lymphocyte Therapies Market Report

The market dynamics surrounding TIL therapies are undergoing a profound transformation, fueled by rising interest in personalized immunotherapy and strong clinical validation. A pivotal milestone occurred in 2024 when the U.S. FDA approved AMTAGVI, making it the first TIL therapy to receive regulatory clearance. This approval not only validated decades of research but also significantly boosted investor confidence and clinical interest in the modality.

One of the primary drivers of growth is the substantial unmet need in solid tumor oncology. While checkpoint inhibitors have revolutionized cancer treatment, many patients either do not respond or eventually develop resistance. TIL therapy offers a compelling alternative by targeting multiple tumor-specific neoantigens, thereby overcoming mechanisms of immune evasion. Advances in manufacturing technologies, including automated closed systems and improved cell expansion techniques, are also helping to address longstanding challenges related to production complexity and turnaround time.

The competitive landscape is becoming increasingly dynamic, with a growing number of biotechnology companies and research institutions entering the TIL space. Strategic collaborations, licensing agreements, and mergers and acquisitions are shaping the industry as organizations seek to enhance their technological capabilities and expand their pipelines. Differentiation strategies include the use of gene editing, improved TIL selection processes, and combination therapies with checkpoint inhibitors.

Despite the optimistic outlook, several challenges remain. High manufacturing costs, complex logistics, and the need for specialized infrastructure continue to limit widespread adoption. Reimbursement issues and regulatory complexities also pose barriers, while biomarker-driven patient selection remains an area requiring further refinement. However, emerging technologies such as artificial intelligence for neoantigen identification, advanced cryopreservation methods, and decentralized manufacturing models hold promise in addressing these limitations over time.

TIL therapy itself represents a next-generation treatment paradigm within the broader category of adoptive cell therapy. The process involves extracting lymphocytes directly from a patient’s tumor, expanding them in a laboratory, and reinfusing them after lymphodepleting chemotherapy. This approach leverages naturally occurring, tumor-reactive T cells that are already primed to recognize cancer-specific antigens. Unlike engineered therapies such as CAR-T or TCR-based treatments, TIL therapy utilizes polyclonal T cells capable of targeting a wide range of tumor neoantigens, making it particularly suitable for heterogeneous solid tumors.

The approval of AMTAGVI marked a watershed moment for the field. This autologous T cell therapy is indicated for adult patients with unresectable or metastatic melanoma who have previously been treated with a PD-1 inhibitor, and in certain cases, BRAF-targeted therapy. By reinfusing activated TILs, the therapy aims to restore the immune system’s ability to recognize and attack tumor cells. Ongoing studies are also evaluating its potential in other indications, including NSCLC and cervical cancer, both as a monotherapy and in combination with checkpoint inhibitors.

Learn more about the tumor-infiltrating lymphocyte therapies @ Tumor-Infiltrating Lymphocyte Therapies Analysis

The pipeline of emerging TIL therapies continues to expand, with several candidates in early-stage clinical development targeting a variety of solid tumors. Among them, OBX-115 stands out due to its innovative design. Developed using Obsidian Therapeutics’ cytoDRIVE platform, this therapy involves engineering TILs to express membrane-bound interleukin-15, enhancing their survival and anti-tumor activity while eliminating the need for high-dose IL-2. A unique drug-responsive mechanism allows clinicians to control expression levels using acetazolamide, adding a layer of safety and flexibility. In September 2024, OBX-115 received Regenerative Medicine Advanced Therapy designation from the FDA for melanoma patients who are refractory to checkpoint inhibitors.

To know more about tumor-infiltrating lymphocyte therapies clinical trials, visit @ Tumor-Infiltrating Lymphocyte Therapies Treatment

From a scientific standpoint, TIL therapy offers a biologically compelling approach to cancer treatment. By expanding tumor-resident T cells ex vivo and reinfusing them into a lymphodepleted patient, the therapy amplifies a naturally occurring immune response. Clinical evidence has demonstrated durable responses in cancers such as metastatic melanoma, cervical cancer, and NSCLC, even among patients who have failed prior immunotherapies.

The epidemiological analysis included in the report spans from 2020 to 2034 and covers the seven major markets, providing segmentation across total cases, eligible patient populations, and treated cases for selected indications. This data-driven approach enables stakeholders to better understand the evolving landscape and identify areas of high unmet need and commercial opportunity.

Overall, the tumor-infiltrating lymphocyte therapy market is transitioning from a research-driven niche to a commercially viable segment of oncology. With continued clinical success, regulatory support, and technological innovation, TIL therapies are poised to play an increasingly important role in the future of cancer treatment.

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

DelveInsight’s “Tumor-infiltrating Lymphocytes (TIL) Therapies – Epidemiology Forecast – 2034” report delivers an in-depth understanding of TIL therapies, historical and forecasted epidemiology of TIL therapies in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The leading companies are Iovance Biotherapeutics, REPROCELL, Curacell Holding, Intima Bioscience, KSQ Therapeutics, Obsidian Therapeutics, AgonOx, NeogenTC, BioSyngen, and others.

Media Contact

Company Name: DelveInsight Business Research LLP

Contact Person: Abhishek kumar

Email: [email protected]

City: Albany

State: New York

Country: United States

Website: https://www.delveinsight.com